Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

This transaction was part of a "Sell to Cover" exercise, automatically implemented to satisfy tax withholding obligations and associated costs. Following this transaction, Mr. Lunger retains ownership ...

In a recent transaction, Norry Elliot, the Chief Medical (TASE:PMCN) Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), executed a sale of 5,584 American Depositary Shares (ADS) on January 17 ...

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday .The stock has a 50-day moving average of $0.62 and ...

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade FDA approves Adaptimmune Therapeutics' Tecelra ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Adaptimmune Therapeutics ( (ADAP)) has shared an update. Adaptimmune Therapeutics announced structural changes ...

Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and Adaptimmune Therapeutics plc (ADAP) 10-day simple moving average is 0.58. Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and ...